Interpace Diagnostics Group Inc (NASDAQ:IDXG) has been given an average rating of “Buy” by the seven research firms that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $3.55.
Several equities research analysts recently commented on the company. Zacks Investment Research upgraded Interpace Diagnostics Group from a “sell” rating to a “hold” rating in a report on Wednesday, January 9th. ValuEngine upgraded Interpace Diagnostics Group from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. HC Wainwright set a $3.00 price objective on Interpace Diagnostics Group and gave the company a “buy” rating in a research note on Tuesday, November 27th. Maxim Group set a $4.00 price objective on Interpace Diagnostics Group and gave the company a “buy” rating in a research note on Monday, November 26th. Finally, Dawson James started coverage on Interpace Diagnostics Group in a research note on Wednesday, October 17th. They set a “buy” rating and a $4.00 price objective for the company.
Hedge funds and other institutional investors have recently modified their holdings of the business. Virtu Financial LLC grew its stake in Interpace Diagnostics Group by 18.4% during the 4th quarter. Virtu Financial LLC now owns 89,036 shares of the business services provider’s stock valued at $71,000 after purchasing an additional 13,846 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in Interpace Diagnostics Group during the 3rd quarter valued at approximately $194,000. Essex Investment Management Co. LLC acquired a new stake in Interpace Diagnostics Group during the 3rd quarter valued at approximately $465,000. Finally, Perkins Capital Management Inc. acquired a new stake in Interpace Diagnostics Group during the 3rd quarter valued at approximately $983,000. Hedge funds and other institutional investors own 16.01% of the company’s stock.
Shares of NASDAQ:IDXG traded up $0.05 during mid-day trading on Friday, hitting $0.98. 459,951 shares of the company traded hands, compared to its average volume of 396,496. The company has a market cap of $26.47 million, a P/E ratio of -1.21 and a beta of 2.45. Interpace Diagnostics Group has a 52-week low of $0.76 and a 52-week high of $1.78.
Interpace Diagnostics Group (NASDAQ:IDXG) last announced its earnings results on Tuesday, November 13th. The business services provider reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.04). The company had revenue of $5.75 million for the quarter, compared to analysts’ expectations of $5.50 million. Interpace Diagnostics Group had a negative net margin of 64.40% and a negative return on equity of 33.67%. Equities research analysts expect that Interpace Diagnostics Group will post -0.38 EPS for the current year.
About Interpace Diagnostics Group
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.
Recommended Story: How to Invest in the Dividend Aristocrat Index
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.